TREVENA INC (TRVN) Stock Price, Quote, News and Overview
NASDAQ:TRVN - Nasdaq - US89532E2081 - Common Stock - Currency: USD
TRVN Quote, Performance and Key Statistics
2.5
-2.11 (-45.71%)
The current stock price of TRVN is 2.5 USD. In the past month the price decreased by -50.98%. In the past year, price decreased by -82.14%.
TRVN Competitors/Peers
Symbol | Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 19.97 | 357.10B | ||
| AMGN | AMGEN INC | 15.29 | 162.72B | ||
| GILD | GILEAD SCIENCES INC | 23.85 | 137.00B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 1669.79 | 124.40B | ||
| REGN | REGENERON PHARMACEUTICALS | 15.34 | 76.56B | ||
| ARGX | ARGENX SE - ADR | N/A | 39.16B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | N/A | 32.32B | ||
| BNTX | BIONTECH SE-ADR | N/A | 28.77B | ||
| ONC | BEIGENE LTD-ADR | N/A | 27.25B | ||
| NTRA | NATERA INC | N/A | 21.43B | ||
| BIIB | BIOGEN INC | 8.54 | 20.49B | ||
| SMMT | SUMMIT THERAPEUTICS INC | N/A | 16.31B |
Related stock screener links
About TRVN
Company Profile
Trevena, Inc. is a biopharmaceutical company, which focuses on developing and commercializing novel medicines for patients affected by central nervous system, or CNS, disorders. The company is headquartered in Chesterbrook, Pennsylvania and currently employs 23 full-time employees. The company went IPO on 2014-01-31. The firm has one approved product in the United States, OLINVYK (oliceridine) injection, indicated in adults for the management of acute pain severe enough to require an intravenous opioid analgesic and for whom alternative treatments are inadequate. The Company’s pipeline includes three differentiated investigational drug candidates: TRV045 for diabetic neuropathic pain and epilepsy, TRV250 for the acute treatment of migraine and TRV734 for maintenance treatment of opioid use disorder. TRV045 is a novel, highly selective sphingosine-1-phosphate subtype 1 (S1P1) receptor modulator being developed as a potential treatment for acute and chronic neuropathic pain secondary to diabetic peripheral neuropathy. TRV734 is a small molecule G-protein biased ligand of the mu opioid receptor (MOR).
Company Info
TREVENA INC
955 Chesterbrook Boulevard, Suite 110
Chesterbrook PENNSYLVANIA 19087 US
CEO: Carrie L. Bourdow
Employees: 23
Company Website: https://www.trevena.com/
Phone: 16103548840
TREVENA INC / TRVN FAQ
What is the stock price of TREVENA INC today?
The current stock price of TRVN is 2.5 USD. The price decreased by -45.71% in the last trading session.
What is the ticker symbol for TREVENA INC stock?
The exchange symbol of TREVENA INC is TRVN and it is listed on the Nasdaq exchange.
On which exchange is TRVN stock listed?
TRVN stock is listed on the Nasdaq exchange.
What is the price forecast or stock price prediction for TREVENA INC stock?
8 analysts have analysed TRVN and the average price target is 102 USD. This implies a price increase of 3980% is expected in the next year compared to the current price of 2.5. Check the TREVENA INC stock analysts ratings, price target forecast and up-and down grades for more detailed information.
What is TREVENA INC worth?
TREVENA INC (TRVN) has a market capitalization of 2.13M USD. This makes TRVN a Nano Cap stock.
How many employees does TREVENA INC have?
TREVENA INC (TRVN) currently has 23 employees.
What are the support and resistance levels for TREVENA INC (TRVN) stock?
TREVENA INC (TRVN) has a resistance level at 4.36. Check the full technical report for a detailed analysis of TRVN support and resistance levels.
Is TREVENA INC (TRVN) expected to grow?
The Revenue of TREVENA INC (TRVN) is expected to decline by -95.22% in the next year. Check the estimates tab for more information on the TRVN EPS, Sales, EBIT and EBITDA future analyst estimates.
Should I buy TREVENA INC (TRVN) stock?
There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:
- The Technical Analysis (TA) tab contains a technical analysis of TRVN, looking at technical quality and support and resistance levels
- The Fundamental Analysis (FA) tab contains a fundamental analysis of TRVN, evaluating the profitability, health, valuation and growth aspects
- TREVENA INC (TRVN) Price Target Forecast and Analysts Ratings to understand what professional analysts say.
- TREVENA INC (TRVN) Sales and EPS estimates to see what analysts future expectations are.
- TREVENA INC (TRVN) Income, Balance Sheet and Cash Flow statements to dive into the historical financials.
- TREVENA INC (TRVN) Insider and Institutional Ownership to learn about the owners and their transactions.
- TREVENA INC (TRVN) Stock Chart to make your own analysis
- TREVENA INC (TRVN) Latest news and press-releases to stay up to date.
Does TREVENA INC (TRVN) stock pay dividends?
TRVN does not pay a dividend.
When does TREVENA INC (TRVN) report earnings?
TREVENA INC (TRVN) will report earnings on 2024-11-12, before the market open.
What is the Price/Earnings (PE) ratio of TREVENA INC (TRVN)?
TREVENA INC (TRVN) does not have a PE ratio as the earnings reported over the last twelve months were negative (-16.38).
What is the Short Interest ratio of TREVENA INC (TRVN) stock?
The outstanding short interest for TREVENA INC (TRVN) is 0.84% of its float. Check the ownership tab for more information on the TRVN short interest.
TRVN Technical Analysis
TRVN Fundamental Analysis
ChartMill assigns a fundamental rating of 2 / 10 to TRVN. TRVN has a bad profitability rating. Also its financial health evaluation is rather negative.
TRVN Financial Highlights
Over the last trailing twelve months TRVN reported a non-GAAP Earnings per Share(EPS) of -16.38. The EPS decreased by -265.62% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -264.95% | ||
| ROE | N/A | ||
| Debt/Equity | N/A |
TRVN Ownership and Analysts
ChartMill assigns a Buy % Consensus number of 83% to TRVN. The Buy consensus is the average rating of analysts ratings from 8 analysts.
For the next year, analysts expect an EPS growth of -916.33% and a revenue growth -95.22% for TRVN